LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Resolve Molecular Structure of Critical Ubiquitin-Binding Enzyme

By LabMedica International staff writers
Posted on 03 Feb 2016
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).
The molecular structure of a protein complex critically involved in diverse cellular functions such as cell signaling, DNA repair, and mounting anti-inflammatory and immune responses has been elucidated and presented in a recent paper.

Ubiquitination is a central process affecting all facets of cellular signaling and function. A critical step in ubiquitination is the transfer of the small regulatory protein ubiquitin from an E2 ubiquitin-conjugating enzyme to a substrate or a growing ubiquitin chain, which is mediated by E3 ubiquitin ligases.

Linear ubiquitin chains are important regulators of cellular signaling pathways that control innate immunity and inflammation through nuclear factor (NF)-kappaB activation and protection against tumor necrosis factor-alpha-induced apoptosis. They are synthesized by HOIP (ring finger protein 31), which belongs to the RBR (RING-between-RING) family of E3 ligases and is the catalytic component of LUBAC (linear ubiquitin chain assembly complex), a multisubunit E3 ligase.

Investigators at the Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA, USA) presented—for what might be the first time—the structure of the fully active human HOIP RBR in its transfer complex with an E2-ubiquitin conjugate, which elucidated the intricate nature of the RBR E3 ligases.

They reported in the January 20, 2016, online edition of the journal Nature that the active HOIP RBR adopted a conformation markedly different from that of auto-inhibited RBRs. Furthermore, RBR bound the E2~ubiquitin conjugate in an elongated fashion, with the E2 and E3 catalytic centers ideally aligned for ubiquitin transfer.

"We were surprised to find how the active form of the E3 ligase we analyzed, called HOIP, attaches ubiquitin in a markedly different way - an elongated fashion - compared to the other types of E3 ligases," said senior author Dr. Stefan Riedl, an associate professor in the NCI-designated Cancer Center at the Sanford Burnham Prebys Medical Discovery Institute. "This may be key to its role in activating the NF-kappaB pathway, a signaling process that is well established as a regulator of cell survival and death, and helps coordinate the immune system. NF-kappaB is the master regulator of inflammation inside cells, and its activation is believed to promote cancer development by inhibiting cell death and promoting inflammation. This study removes a significant technical barrier that has prevented exploiting RBR E3 ligases as a drug target for cancer and inflammatory disorders. Our next step is to continue to work very closely with our biology and immunology collaborators to more fully understand the regulation of RBR E3 ligases."

Related Links:

Sanford Burnham Prebys Medical Discovery Institute


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more